1374298-71-1Relevant articles and documents
Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series – Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2
Muthukaman, Nagarajan,Deshmukh, Sanjay,Tambe, Macchindra,Pisal, Dnyandeo,Tondlekar, Shital,Shaikh, Mahamadhanif,Sarode, Neelam,Kattige, Vidya G.,Sawant, Pooja,Pisat, Monali,Karande, Vikas,Honnegowda, Srinivasa,Kulkarni, Abhay,Behera, Dayanidhi,Jadhav, Satyawan B.,Sangana, Ramchandra R.,Gudi, Girish S.,Khairatkar-Joshi, Neelima,Gharat, Laxmikant A.
, p. 1211 - 1218 (2018/03/12)
In an effort to identify CYP and hERG clean mPGES-1 inhibitors from the dihydrofuran-fused tricyclic benzo[d]imidazole series lead 7, an extensive structure-activity relationship (SAR) studies were performed. Optimization of A, D and E-rings in 7 afforded many potent compounds with human whole blood potency in the range of 160–950 nM. Selected inhibitors 21d, 21j, 21m, 21n, 21p and 22b provided selectivity against COX-enzymes and mPGES-1 isoforms (mPGES-2 and cPGES) along with sufficient selectivity against prostanoid synthases. Most of the tested analogs demonstrated required metabolic stability in liver microsomes, low hERG and CYP liability. Oral pharmacokinetics and bioavailability of lead compounds 21j, 21m and 21p are discussed in multiple species like rat, guinea pig, dog, and cynomolgus monkey. Besides, these compounds revealed low to moderate activity against human pregnane X receptor (hPXR). The selected lead 21j further demonstrated in vivo efficacy in acute hyperalgesia (ED50: 39.6 mg/kg) and MIA-induced osteoarthritic pain models (ED50: 106 mg/kg).
